Nxera PharmaNxera Pharma Co., Ltd.4565東証プライム医薬品FY ending Dec 2023, consolidated, IFRS

What does Nxera Pharma do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

Figures for this period are incomplete, so the chart cannot be drawn.

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income-¥7.19B

Operating cash flow-¥5.27B

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow-¥5.27B

Net income-¥7.19B

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (4)

EDINET (FSA Japan)
有価証券報告書－第36期(2025/01/01－2025/12/31)
ID S100XTYN2026-03-25Open
EDINET (FSA Japan)
有価証券報告書－第33期(2022/01/01－2022/12/31)
ID S100QFQ72023-03-23Open
EDINET (FSA Japan)
有価証券報告書－第32期(令和3年1月1日－令和3年12月31日)
ID S100NQA22022-03-24Open
EDINET (FSA Japan)
有価証券報告書－第31期(令和2年1月1日－令和2年12月31日)
ID S100L0R42021-03-24Open

Extracted from XBRL: 10 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.